Dasatinib in Combination With Revlimid (and Dexamethasone)
Public ClinicalTrials.gov record NCT00560391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) With Lenalidomide (Revlimid®) and Dexamethasone in Subjects With Relapsed and/ or Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT00560391
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg Drug
- Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg Drug
- Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg Drug
- Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg Drug
- Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Sep 30, 2011
- Completion
- Oct 31, 2012
- Last update posted
- Aug 3, 2016
2008 – 2012
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00560391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2016 · Synced Apr 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00560391 live on ClinicalTrials.gov.